Coherus Oncology, Inc. 8-K

What Happened
Coherus Oncology, Inc. (CHRS) announced that it entered into an underwriting agreement dated February 12, 2026, and completed a public offering on February 17, 2026. The company sold 28,600,000 shares of common stock at $1.75 per share (underwriters purchased at $1.645 per share), resulting in net proceeds of approximately $47.0 million after underwriters’ discounts and commissions (before estimated offering expenses).

Key Details

• Offering size: 28,600,000 firm shares sold on February 17, 2026.
• Pricing: Public offering price $1.75 per share; underwriters’ purchase price $1.645 per share.
• Overallotment option: Underwriters have a 30-day option to buy up to an additional 4,290,000 shares to cover any over-allotments.
• Lock-up: The company, its directors, executive officers and certain affiliated stockholders agreed not to sell or transfer common stock for 60 days from February 12, 2026 (subject to customary exceptions).
• Documents: Underwriting agreement and legal opinion of Latham & Watkins LLP filed as exhibits to the 8-K.

Why It Matters
This offering provides Coherus Oncology with roughly $47 million in additional capital, which can impact the company's cash runway and strategic options. The issuance increases the number of shares outstanding (dilution to existing shareholders) and includes a 60-day insider lock-up, which limits insider sales in the short term. Investors should note the underwriters’ 30-day overallotment option could increase dilution if exercised.